cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.21551465.v1
title: Enhanced chemical weathering of the continents promoted fast Late Cretaceous nearshore glaucony formation: implications from the Danubian Cretaceous Group, Germany

description: Supplementary Table S1 provides contents of total carbon (TC), total inorganic carbon (TIC), total organic carbon (TOC), major elements and Zr as well as element/Al ratios, calculated excess K (K<sub>xs</sub>), silicate K (K<sub>sil</sub> or K<sub>2</sub>O<sub>sil</sub>), molar element oxides and CIX values. Bold sample IDs: marine samples, data in italics: below quantification limit (0.1 wt %), data in bold and italics: silicate K<sub>2</sub>O necessary for CIX calculation, na: not analyzed.
DOI: 10.6084/m9.figshare.19714639
title: Trial look-up table

description: Look-up table that shows the gait condition (i.e. speed, step length, step frequency, step width) for each trial number (1-33)
DOI: 10.6084/m9.figshare.19718500
title: Level 1 - C3D files

description: Raw C3D data files, containing ground reaction forces obtained from force platforms and marker positions obtained from motion capture system
DOI: 10.6084/m9.figshare.21341055
title: Level 2 - CMO files

description: CMO data files, containing biomechanical variables such as joint moments, forces and powers computed with Visual3D software
DOI: 10.6084/m9.figshare.21341784
title: Level 3 - MATLAB files

description: MAT data files, containing biomechanical variables such as joint moments, forces and powers computed with Visual3D software
DOI: 10.34740/kaggle/dsv/4509866
title: YouTube Trending Video Dataset (updated daily)
DOI: 10.34740/kaggle/dsv/4509886
title: Elon Musk Tweets
DOI: 10.34740/kaggle/dsv/4509891
title: 2021 World Population (updated daily)
DOI: 10.6084/m9.figshare.14695176
title: Web of Science categories (WC, SC, main categories) and ESI disciplines mapping

description: Mapping of Research Area (SC), Web of Science Category (WC), five main categories, and ESI disciplines.<br>
DOI: 10.5281/zenodo.7319212
title: Data for MILP algorithm for control strategy optimisation of a hybrid solar thermal plant consisting of two different solar fields working for two processes at different temperatures, a three tanks storage and a boiler for SHIP applications

description: This repository contains the results of simulations exposed in the article <strong>MILP algorithm for control strategy optimisation of a hybrid solar thermal plant consisting of two different solar fields working for two processes at different temperatures, a three tanks storage and a boiler for SHIP applications.</strong> Notebooks for easy plotting of the results are contained in this repository. The README.txt contains light explainations regarding how to use those notebooks. This article is yet to be published at the time of writing.
DOI: 10.5281/zenodo.7319211
title: Data for MILP algorithm for control strategy optimisation of a hybrid solar thermal plant consisting of two different solar fields working for two processes at different temperatures, a three tanks storage and a boiler for SHIP applications

description: This repository contains the results of simulations exposed in the article <strong>MILP algorithm for control strategy optimisation of a hybrid solar thermal plant consisting of two different solar fields working for two processes at different temperatures, a three tanks storage and a boiler for SHIP applications.</strong> Notebooks for easy plotting of the results are contained in this repository. The README.txt contains light explainations regarding how to use those notebooks. This article is yet to be published at the time of writing.
DOI: 10.6084/m9.figshare.20485026.v1
title: Symptoms and diagnosis of local recurrence after rectal cancer treatment

description: The prognosis for local recurrence after rectal cancer treatment is poor. A minority of patients are eligible for surgery with curative intent, which could possibly be improved by earlier detection. The aim of this study was to determine symptoms at presentation and how local recurrence was diagnosed, and to identify alarm symptoms for local recurrence as opposed to symptoms found among patients after surgery for rectal cancer in general. In a population-based retrospective cohort (cohort A), all patients who had undergone resection surgery for rectal cancer in the region of Västra Götaland, Sweden, diagnosed 2010–2014, were identified through the Swedish ColoRectal Cancer Registry. After a follow-up period of at least five years, medical records were reviewed to identify patients diagnosed with local recurrence. Data on symptoms, diagnostic procedures and treatment of local recurrence were retrieved. A prospective cohort of patients who had undergone surgery for rectal cancer without local recurrence (the QoLiRECT-study, cohort B) was used for comparison regarding symptoms at two years after treatment. Cohort A consisted of 1208 patients, out of whom 78 (6%) were diagnosed with local recurrence. Forty-six patients were diagnosed between scheduled follow-up visits. Fifty-eight patients were symptomatic at the time of diagnosis, and the most common symptoms were pain, bleeding and urogenital symptoms. Pain was more common in patients with local recurrence when comparing cohort A with cohort B. A majority of patients with local recurrence were diagnosed outside of the scheduled follow-up. Most of the patients were symptomatic at diagnosis. Symptoms were common in patients after rectal cancer surgery in general, however pain was more common in patients with local recurrence and could represent an alarm symptom.
DOI: 10.6084/m9.figshare.20485026
title: Symptoms and diagnosis of local recurrence after rectal cancer treatment

description: The prognosis for local recurrence after rectal cancer treatment is poor. A minority of patients are eligible for surgery with curative intent, which could possibly be improved by earlier detection. The aim of this study was to determine symptoms at presentation and how local recurrence was diagnosed, and to identify alarm symptoms for local recurrence as opposed to symptoms found among patients after surgery for rectal cancer in general. In a population-based retrospective cohort (cohort A), all patients who had undergone resection surgery for rectal cancer in the region of Västra Götaland, Sweden, diagnosed 2010–2014, were identified through the Swedish ColoRectal Cancer Registry. After a follow-up period of at least five years, medical records were reviewed to identify patients diagnosed with local recurrence. Data on symptoms, diagnostic procedures and treatment of local recurrence were retrieved. A prospective cohort of patients who had undergone surgery for rectal cancer without local recurrence (the QoLiRECT-study, cohort B) was used for comparison regarding symptoms at two years after treatment. Cohort A consisted of 1208 patients, out of whom 78 (6%) were diagnosed with local recurrence. Forty-six patients were diagnosed between scheduled follow-up visits. Fifty-eight patients were symptomatic at the time of diagnosis, and the most common symptoms were pain, bleeding and urogenital symptoms. Pain was more common in patients with local recurrence when comparing cohort A with cohort B. A majority of patients with local recurrence were diagnosed outside of the scheduled follow-up. Most of the patients were symptomatic at diagnosis. Symptoms were common in patients after rectal cancer surgery in general, however pain was more common in patients with local recurrence and could represent an alarm symptom.
DOI: 10.6084/m9.figshare.21111410
title: Patterns of relapse and long-term outcome in patients treated with a curative intent for advanced Hodgkin lymphoma

description: Consolidation radiotherapy for advanced Hodgkin lymphoma (AHL) is controversial. Precise knowledge of the most likely relapse location is crucial for radiotherapy planning. We performed detailed patterns of relapse analyses and evaluated if initial bulky disease, initial 18F-fluoro-deoxy-glucose (FDG)-avidity and/or a residual mass on computed tomography (CT)-scan after chemotherapy are sites with a high risk of relapse. This information could provide guidance for optimal use of radiotherapy in AHL. We included 133 patients treated with curatively intended chemotherapy for AHL. 23 patients received consolidation radiotherapy. For relapsed patients, imaging from diagnosis, response evaluation, relapse, and any radiotherapy planning, were retrieved and co-registered to determine the exact site(s) of relapse relative to initial site(s), residual mass(es) and to any irradiated volumes. Size and FDG-avidity of initial sites with later relapse, and residual CT-abnormalities after chemotherapy in these sites were registered. Survival analyses were done using the Kaplan–Meier method. Nine (6.8%) patients relapsed, eight in initially involved sites. One relapse was in an initially irradiated site (as well as other sites). Initial bulky disease, high initial FDG-uptake, and/or residual masses on CT-scan after chemotherapy did not predict sites with a high risk of relapse. Overall survival was 79.6% (95% CI, 72.7–86.5%) and 70.6% (95% CI, 62.4–78.8%) at 5 and 10 years, respectively. Time to progression analysis showed 91.8% (95% CI, 86.9–96.7%) and 90.7% (95% CI, 85.4–96.0%) without progression at 5 and 10 years, respectively. Current treatment strategies for AHL provide excellent disease control. Neither initial bulk, high initial FDG-uptake, nor a residual CT-abnormality post-chemotherapy seem to indicate sites with a high risk of relapse.
DOI: 10.6084/m9.figshare.20651971
title: Patterns of care in oligometastatic disease: the clinicians’ perspective

description: Patterns of care in oligometastatic disease: the clinicians’ perspective
DOI: 10.6084/m9.figshare.20651971.v1
title: Patterns of care in oligometastatic disease: the clinicians’ perspective

description: Patterns of care in oligometastatic disease: the clinicians’ perspective
DOI: 10.6084/m9.figshare.21111410.v1
title: Patterns of relapse and long-term outcome in patients treated with a curative intent for advanced Hodgkin lymphoma

description: Consolidation radiotherapy for advanced Hodgkin lymphoma (AHL) is controversial. Precise knowledge of the most likely relapse location is crucial for radiotherapy planning. We performed detailed patterns of relapse analyses and evaluated if initial bulky disease, initial 18F-fluoro-deoxy-glucose (FDG)-avidity and/or a residual mass on computed tomography (CT)-scan after chemotherapy are sites with a high risk of relapse. This information could provide guidance for optimal use of radiotherapy in AHL. We included 133 patients treated with curatively intended chemotherapy for AHL. 23 patients received consolidation radiotherapy. For relapsed patients, imaging from diagnosis, response evaluation, relapse, and any radiotherapy planning, were retrieved and co-registered to determine the exact site(s) of relapse relative to initial site(s), residual mass(es) and to any irradiated volumes. Size and FDG-avidity of initial sites with later relapse, and residual CT-abnormalities after chemotherapy in these sites were registered. Survival analyses were done using the Kaplan–Meier method. Nine (6.8%) patients relapsed, eight in initially involved sites. One relapse was in an initially irradiated site (as well as other sites). Initial bulky disease, high initial FDG-uptake, and/or residual masses on CT-scan after chemotherapy did not predict sites with a high risk of relapse. Overall survival was 79.6% (95% CI, 72.7–86.5%) and 70.6% (95% CI, 62.4–78.8%) at 5 and 10 years, respectively. Time to progression analysis showed 91.8% (95% CI, 86.9–96.7%) and 90.7% (95% CI, 85.4–96.0%) without progression at 5 and 10 years, respectively. Current treatment strategies for AHL provide excellent disease control. Neither initial bulk, high initial FDG-uptake, nor a residual CT-abnormality post-chemotherapy seem to indicate sites with a high risk of relapse.
DOI: 10.6084/m9.figshare.20473117
title: Shifting gears to differentiation agents in acute promyelocytic leukemia with resource constraints—a cohort study

description: Treatment of acute promyelocytic leukaemia has emerged as a major success in hemato-oncology. While literature from the developed world boasts of outstanding outcomes, there is a paucity of data from the developing world. This study aimed to assess complications and outcomes of acute promyelocytic leukaemia in a resource-constrained setting. We retrospectively collected data from patients diagnosed with APL from January 2016 to December 2020. Sixty-four patients were treated-32 in both the Sanz high and low-risk groups. In the Sanz low-risk group, 12.5% of patients received ATRA with daunorubicin and 81.25% received ATRA with ATO. In the Sanz high-risk group, 18.8% of patients received ATRA with daunorubicin, 34.3% received ATRA with daunorubicin and ATO while 40.6% received ATRA with ATO. 56.25% of patients developed differentiation syndrome. The incidence was higher in Sanz high-risk group as compared to Sanz low-risk group. 57.4% of patients had an infection at the time of presentation. 62.5% of patients developed neutropenic fever during treatment. 17.2% of patients developed pseudotumor cerebri. The 4-year EFS and OS were 71.25 and 73.13%, respectively. Sanz low-risk group had a better 4-year EFS and OS as compared to the Sanz high-risk group. Haemoglobin at presentation and Sanz high-risk group were associated with poorer outcomes with a hazard ratio of 0.8 and 3.1, respectively. Outcomes in high-risk patients were better with the use of ATRA + ATO + daunorubicin. In the Indian population, APL patients have a high incidence of differentiation syndrome, pseudotumor cerebri, and infections during induction. CR, EFS, and OS compared to the developed world can be achieved with optimal therapy. Low haemoglobin at presentation and Sanz high-risk group were associated with poorer outcomes. ATRA, ATO, and daunorubicin combination is the preferred protocol for treating high-risk patients.
DOI: 10.6084/m9.figshare.20497238
title: Lung cancer with dual <i>EGFR</i> and <i>ALK</i> driver alterations at baseline: a retrospective observational cohort study

description: Lung cancer with dual <i>EGFR</i> and <i>ALK</i> driver alterations at baseline: a retrospective observational cohort study
DOI: 10.6084/m9.figshare.21070902
title: Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy

description: Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy
DOI: 10.6084/m9.figshare.20497238.v1
title: Lung cancer with dual <i>EGFR</i> and <i>ALK</i> driver alterations at baseline: a retrospective observational cohort study

description: Lung cancer with dual <i>EGFR</i> and <i>ALK</i> driver alterations at baseline: a retrospective observational cohort study
DOI: 10.6084/m9.figshare.21070902.v1
title: Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy

description: Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy
DOI: 10.6084/m9.figshare.20473117.v1
title: Shifting gears to differentiation agents in acute promyelocytic leukemia with resource constraints—a cohort study

description: Treatment of acute promyelocytic leukaemia has emerged as a major success in hemato-oncology. While literature from the developed world boasts of outstanding outcomes, there is a paucity of data from the developing world. This study aimed to assess complications and outcomes of acute promyelocytic leukaemia in a resource-constrained setting. We retrospectively collected data from patients diagnosed with APL from January 2016 to December 2020. Sixty-four patients were treated-32 in both the Sanz high and low-risk groups. In the Sanz low-risk group, 12.5% of patients received ATRA with daunorubicin and 81.25% received ATRA with ATO. In the Sanz high-risk group, 18.8% of patients received ATRA with daunorubicin, 34.3% received ATRA with daunorubicin and ATO while 40.6% received ATRA with ATO. 56.25% of patients developed differentiation syndrome. The incidence was higher in Sanz high-risk group as compared to Sanz low-risk group. 57.4% of patients had an infection at the time of presentation. 62.5% of patients developed neutropenic fever during treatment. 17.2% of patients developed pseudotumor cerebri. The 4-year EFS and OS were 71.25 and 73.13%, respectively. Sanz low-risk group had a better 4-year EFS and OS as compared to the Sanz high-risk group. Haemoglobin at presentation and Sanz high-risk group were associated with poorer outcomes with a hazard ratio of 0.8 and 3.1, respectively. Outcomes in high-risk patients were better with the use of ATRA + ATO + daunorubicin. In the Indian population, APL patients have a high incidence of differentiation syndrome, pseudotumor cerebri, and infections during induction. CR, EFS, and OS compared to the developed world can be achieved with optimal therapy. Low haemoglobin at presentation and Sanz high-risk group were associated with poorer outcomes. ATRA, ATO, and daunorubicin combination is the preferred protocol for treating high-risk patients.
DOI: 10.5519/qd.lu2aczns
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (14 records)
DOI: 10.25934/pr00005281.0
title: Available IPD datapackage for study 'A 24-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel Group Study to Compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)'

description: COPD is characterized by an airflow limitation, which is not fully reversible, usually progressive and accompanied by chronic cough, sputum production and dyspnea, which can be a major cause of disability and anxiety associated with the disease. In addition, COPD is associated with poor health-related quality of life (HRQoL). Pharmacologic therapy is used to improve lung function, reduce symptoms, reduce the frequency and severity of exacerbations, and also to improve health status and exercise tolerance. This is a multi-center, randomized, double blind, double dummy, 3-arm parallel group study to compare umeclidinium/vilanterol (62.5/25 microgram [mcg], once daily), umeclidinium (62.5 mcg, once daily), and salmeterol (50 mg, twice daily) in male and female subjects with COPD. The primary purpose of this study is to demonstrate improvements in lung function for subjects treated with UMEC/VI compared with UMEC for 24 weeks. Approximately 2424 subjects will be randomized across 3 parallel arms in 1:1:1 ratio. Subjects will be stratified based on long-acting bronchodilator usage during the run-in period (none, one or 2 long-acting bronchodilators per day). Subjects will receive either UMEC/VI inhalation powder (62.5/25 microgram [mcg] once daily) administered via the ELLIPTA® dry powder inhaler (DPI) and placebo twice daily via DISKUS® DPI; or UMEC (62.5 mcg once daily) administered via the ELLIPTA DPI and placebo twice daily via DISKUS DPI or salmeterol (50 mcg twice daily [BID]) administered via the DISKUS DPI and placebo once daily via ELLIPTA DPI. The duration of the study will be 29 to 31 weeks including a pre-screening period of 2 weeks, run-in period of 4 weeks, treatment period of 24 weeks and follow-up period of 1 week. ELLIPTA and DISKUS are trademarks of GSK group of companies.
DOI: 10.5281/zenodo.6603525
title: Distribution map of Badorf ware (Northern Europe)

description: Badorf ware, a pottery produced near Cologne (Germany) during the 8th and 9th centuries AD, was widely traded in the North Sea and Baltic area. The two files contain a distribution map (as csv-file) and additional bibliography for Northern Germany and Scandinavia.
DOI: 10.5281/zenodo.6603526
title: Distribution map of Badorf ware (Northern Europe)

description: Badorf ware, a pottery produced near Cologne (Germany) during the 8th and 9th centuries AD, was widely traded in the North Sea and Baltic area. The two files contain a distribution map (as csv-file) and additional bibliography for Northern Germany and Scandinavia.
DOI: 10.5281/zenodo.7319313
title: Distribution map of Badorf ware (Northern Europe)

description: Badorf ware, a pottery produced near Cologne (Germany) during the 8th and 9th centuries AD, was widely traded in the North Sea and Baltic area. The two files contain a distribution map (as csv-file) and additional bibliography for Northern Germany and Scandinavia.
DOI: 10.25934/pr00007782
title:  A new covariate randomization method for multi-arm randomized controlled trials

description: SUMMARY:
Covariates are independent variables that can influence the outcome of a given statistical trial. In causal inference and clinical studies, balancing important covariates is often one of the most important concerns. However, covariates imbalance still exist in many randomized experiments. This phenomenon of covariate imbalance becomes much more serious as the number of covariates p increases. If a significant imbalance exists, any inferences regarding the treatment effect will be inaccurate, and any claims about the treatment effect will need to rely on unverifiable assumptions .
To address this issue, we introduce a new randomization procedure. The proposed method allocates the units sequentially and adaptively, using information on the current level of imbalance and the incoming unit’s covariate. With a large number of covariates or a large number of units, the proposed method shows substantial advantages over the traditional methods in terms of the covariate balance, estimation accuracy, and computational time, making it an ideal technique in the era of big data.  Also the proposed method is widely applicable in both causal inference and clinical trials.